Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Gene Variant Descriptions||ERBB2 (HER2) exon 20 indicates an unspecified mutation has occurred in exon 20 of the ERBB2 (HER2) gene.|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 exon20||lung non-small cell carcinoma||predicted - sensitive||Pyrotinib||Phase II||Actionable||In a Phase II trial, non-small cell lung cancer patients harboring an ERBB2 exon 20 mutation demonstrated an objective response rate of 53.3% (8/15) and a median progression-free survival of 6.4 months when treated with Pyrotinib (PMID: 30596880; NCT02535507).||30596880|
|ERBB2 exon20||lung non-small cell carcinoma||no benefit||Afatinib||Phase II||Actionable||In a Phase II trial, Gilotrif (afatinib) monotherapy was tolerated but did not result in clinical benefit in patients with advanced non-small cell lung cancer harboring ERBB2 (HER2) exon 20 mutations who had not received tyrosine kinase inhibitor therapy, with no patient (0/18) achieved objective response and 61.1% (11/18) of patients achieved stable disease as best response (PMID: 32738416).||32738416|
|Molecular Profile||Protein Effect||Treatment Approaches|